Atlas Trials

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Clinical trial NCT07409272 · RECRUITING

Trial details

NCT number
NCT07409272
Sponsor
Astellas Pharma Global Development, Inc.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Start date
2026-02-17
Primary completion
2029-08-31
Enrollment
614

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.